

1646
BOX Seg

PTO/SB/21 (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	09/749,589
		Filing Date	12/28/2000
		First Named Inventor	GUEGLER, Karl
Total Number of Pages in This Submission		Group Art Unit	1646
		Examiner Name	ULM, John D. JAN 21 2003
		Attorney Docket Number	CL000861 TECH CENTER 1600/2

ENCLOSURES (check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input checked="" type="checkbox"/> Assignment Papers (for an Application) <input checked="" type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Remarks	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Sequence Listing Diskette; and Sequence Listing Submission Statement

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Lin Sun-Hoffman, Ph.D. Reg. No. 47,983
Signature	
Date	01/15/2003

CERTIFICATE OF MAILING		
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 		
Typed or printed name		
Signature	Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

JAN 15 2003

PTO/SB/17 (01-03)

Approved for use through 04/30/2003. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 150)

C mplete if Known

Application Number 09/749,589

Filing Date December 28, 2000

First Named Inventor GUEGLER, Karl et al.

Examiner Name ULM, John D.

Art Unit 1646

Attorney Docket No. CL000861

RECEIVED

JAN 21 2003

TECH CENTER 1600/2900

METHOD OF PAYMENT (check all that apply)

 Check Credit card Money Order Other None Deposit Account:Deposit Account Number
Deposit Account Name

50-0970

CELERA GENOMICS

The Commissioner is authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments

Charge any additional fee(s) during the pendency of this application

Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1001 750	2001 375	Utility filing fee			
1002 330	2002 165	Design filing fee			
1003 520	2003 260	Plant filing fee			
1004 750	2004 375	Reissue filing fee			
1005 160	2005 80	Provisional filing fee			
SUBTOTAL (1) (\$)					

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	-20** =	X	=
Multiple Dependent	- 3** =	X	=

Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20		
1201 84	2201 42	Independent claims in excess of 3		
1203 280	2203 140	Multiple dependent claim, if not paid		
1204 84	2204 42	** Reissue independent claims over original patent		
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent		
SUBTOTAL (2) (\$)				

**or number previously paid, if greater; For Reissues, see above

3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath			
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet			
1053 130	1053 130	Non-English specification			
1812 2,520	1812 2,520	For filing a request for ex parte reexamination			
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action			
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action			
1251 110	2251 55	Extension for reply within first month			
1252 410	2252 205	Extension for reply within second month			
1253 930	2253 465	Extension for reply within third month			
1254 1,450	2254 725	Extension for reply within fourth month			
1255 1,970	2255 985	Extension for reply within fifth month			
1401 320	2401 160	Notice of Appeal			
1402 320	2402 160	Filing a brief in support of an appeal			
1403 280	2403 140	Request for oral hearing			
1451 1,510	1451 1,510	Petition to institute a public use proceeding			
1452 110	2452 55	Petition to revive - unavoidable			
1453 1,300	2453 650	Petition to revive - unintentional			
1501 1,300	2501 650	Utility issue fee (or reissue)			
1502 470	2502 235	Design issue fee			
1503 630	2503 315	Plant issue fee			
1460 130	1460 130	Petitions to the Commissioner			
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)			
1806 180	1806 180	Submission of Information Disclosure Stmt			
8021 40	8021 40	Recording each patent assignment per property (times number of properties)			40
1809 750	2809 375	Filing a submission after final rejection (37 CFR 1.129(a))			
1810 750	2810 375	For each additional invention to be examined (37 CFR 1.129(b))			
1801 750	2801 375	Request for Continued Examination (RCE)			
1802 900	1802 900	Request for expedited examination of a design application			
Other fee (specify) _____					
*Reduced by Basic Filing Fee Paid					
SUBTOTAL (3) (\$ 150)					

(Complete if applicable)

Name (Print/Type)	Lin Sun-Hoffman, Ph.D.	Registration No. (Attorney/Agent)	47,983	Telephone
Signature	Jan. 15, 2003			

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: GUEGLER, Karl et al.

Art Unit: 1646

Serial No.: 09/749,589

Examiner: ULM, John D.

Filed: December 28, 2000

Atty. Docket: CL000861

For: ISOLATED HUMAN TRANSPORTER PROTEINS,
NUCLEIC ACID MOLECULES ENCODING HUMAN
TRANSPORTER PROTEINS, AND USES THEREOF

A handwritten signature in black ink, appearing to read "Lin Sun-Hoffman".

Submission of Formal Drawings

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Attached are 24 sheets of formal drawings (Figs. 1A-1B, 2A-2D, and 3A-3R) for the above-identified application.

Respectfully submitted,

Date: January 15, 2003

By: A handwritten signature in black ink, appearing to read "Lin Sun-Hoffman".

Lin Sun-Hoffman, Reg. 47,983

Celera Genomics
45 West Gude Drive, C2-4#20
Rockville, MD 20850
Tel: 240-453-3067
Fax: 240-453-3084



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: GUEGLER, Karl et al.

Art Unit: 1646

Serial No.: 09/749,589

Examiner: ULM, John D.

Filed: December 28, 2000

Atty. Docket: CL000861

For: ISOLATED HUMAN TRANSPORTER
PROTEINS, NUCLEIC ACID MOLECULES
ENCODING HUMAN TRANSPORTER PROTEINS,
AND USES THEREOF

TH163
RECEIVED

JAN 21 2003

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Communication November 21, 2002, and in compliance with 37 C.F.R. § 1.84, applicants submit a Substitute Sequence Listing, including the paper copy of the Substitute Sequence Listing (12 pages) and the computer readable copy of the Substitute Sequence Listing. The Substitute Sequence Listing includes no new matter.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Substitute Sequence Listing and the computer readable copy of the Substitute Sequence Listing submitted herewith in the above application are the same.

It is respectfully believed that this application complies with the Sequence Listing requirements and is now in condition for processing.

Respectfully submitted,

Date: January 15, 2003

By: 
Lin Sun-Hoffman, Reg. 47,983

Celera Genomics Corporation
45 West Gude Drive, C2-4#20
Rockville, MD 20850
Tel: 240-453-3812
Fax: 240-453-3084